Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Novartis Stepping Up Population Health Initiatives in CV, Oncology Arenas to Solve Regional Challenges
March 30, 2022
- JCR, Takeda Seal R&D Pact on Gene Therapies Using BBB Technology
March 29, 2022
- Kyowa Pharma Hit by Biz Suspension over Manufacturing Flaws, Record Fabrications
March 29, 2022
- Asahi Kasei’s Recomodulin Enters US-Japan PI Study for Chemotherapy-Induced Peripheral Neuropathy
March 29, 2022
- Yakult Honsha Files Blood Cancer Med Duvelisib in Japan
March 25, 2022
- Shionogi Seeks Japan Approval of Novel Antibiotic Cefiderocol
March 25, 2022
- Towa Wins Livalo Damage Suit; Kowa to Appeal Ruling
March 25, 2022
- Fujifilm to Snap Up US Recombinant Protein Manufacturer
March 24, 2022
- Ube Grants Global Rights for CDK7 Inhibitor to Kirilys
March 24, 2022
- Chugai to Scale Down Wholesale Promotion Spend as Portfolio Pivots to Specialty Care: CEO
March 24, 2022
- Lecanemab Scores Positive Results in PIIb Study: Eisai/Biogen
March 23, 2022
- Sales Reps’ Online Detailing Activities Log Double-Digit Rise MOM, YOY in January: Intage
March 23, 2022
- Vectibix/Chemo Extends OS in 1st Line Colorectal Cancer: Japan PIII
March 22, 2022
- Sanofi Files PD-1 Drug Cemiplimab for Cervical Cancer in Japan
March 22, 2022
- Generic Makers, PMDA Exploring GMP Inspection Methods for Overseas Sites; Onsite Checks Not Possible for 2 Years
March 18, 2022
- Chugai Aspires to Grow Beyond 1 Trillion Yen Company: CEO
March 18, 2022
- Biogen Unveils Peer-Reviewed Aduhelm Data 9 Months after FDA OK
March 18, 2022
- Kenei, Maruho Settle Healmild Dispute; Brand Name to Remain with Design Changes
March 18, 2022
- Kyorin Grants Chinese Rights for Lascufloxacin to Local Company
March 18, 2022
- Chugai, Alexion Settle Patent Suits over Ultomiris
March 18, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…